Genmab ADR (GMAB): Next-Year EPS Estimate 48.58%
As of 2026-11-06, Genmab ADR (GMAB) has a next-year EPS growth estimate of 48.58%. Featured in 7 EPS revision reports, most recently on 2026-11-02.
On 2026-11-02, analyst consensus for GMAB's next-year EPS growth shifted from 48.76% to 48.58% — a negative change of 0.18 percentage points. The revised estimate has been sustained across 5 subsequent trading sessions. Current-year growth is projected at -23.28%.
What's Driving This
GMAB's rise has been driven primarily by a structural uplift in next-year EPS growth estimates, which moved from 46.16% to 46.27% on 2026-10-23 and have since risen a net 2.49 pp to 48.76% across three upward and one downward revision. The trend appears supported by positive clinical headlines, particularly statistically significant
Generated 2026-10-30 from news as of 2026-10-30
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 48.58%
- EPS growth this year
- -23.28%
- EPS next quarter (est)
- $0.30
- Last price
- $52.74
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-06 | 48.58% | -23.28% | $0.30 | $52.74 |
| 2026-11-05 | 48.58% | -23.28% | N/A | $52.74 |
| 2026-11-04 | 48.58% | -23.28% | $0.35 | $55.12 |
| 2026-11-03 | 48.58% | -23.28% | $0.35 | $55.52 |
| 2026-11-02 | 48.58% | -23.28% | $0.35 | $54.92 |
| 2026-10-31 | 48.76% | -23.27% | $0.35 | $57.06 |
| 2026-10-30 | 48.76% | -23.27% | $0.35 | $57.06 |
| 2026-10-29 | 48.76% | -23.27% | $0.35 | $56.49 |
| 2026-10-28 | 46.45% | -23.20% | $0.35 | $57.29 |
| 2026-10-27 | 46.31% | -23.23% | $0.35 | $44.67 |
| 2026-10-26 | 46.86% | -23.44% | $0.35 | $44.69 |
| 2026-10-23 | 46.27% | -23.00% | $0.35 | $43.79 |
| 2026-10-22 | 46.16% | -23.00% | $0.35 | $40.00 |
| 2026-10-21 | 46.16% | -23.00% | $0.35 | $39.57 |
| 2026-10-20 | 46.16% | -23.00% | $0.35 | $39.07 |
| 2026-10-19 | 48.79% | -23.15% | $0.36 | $38.50 |
| 2026-10-16 | 46.34% | -23.23% | $0.36 | $37.00 |
| 2026-10-15 | 46.34% | -23.23% | $0.36 | $37.82 |
| 2026-10-14 | 46.34% | -23.23% | $0.36 | $36.89 |
| 2026-10-13 | 46.38% | -23.31% | $0.35 | $36.57 |
| 2026-10-12 | 45.35% | -22.67% | $0.35 | $37.37 |
| 2026-10-11 | 45.35% | -22.67% | $0.35 | $37.07 |
| 2026-10-10 | 45.35% | -22.67% | $0.35 | $37.07 |
| 2026-10-09 | 45.35% | -22.67% | $0.35 | $37.07 |
| 2026-10-08 | 45.66% | -23.25% | $0.35 | $36.05 |
| 2026-10-07 | 45.56% | -23.27% | $0.35 | $36.65 |
| 2026-10-06 | 45.08% | -23.09% | $0.35 | $37.80 |
| 2026-10-05 | 45.07% | -23.18% | $0.35 | $38.48 |
| 2026-10-04 | 44.82% | -23.09% | $0.37 | $34.75 |
| 2026-10-03 | 45.22% | -22.89% | $0.37 | $34.75 |
Reports Featuring GMAB
- 2026-11-02
Healthcare Micro-Caps Lead: COSM +34.8%, NMRA +28.2%, GMAB +25.4% on EPS Revisions
- 2026-10-31
COSM Jumps 34.8% as EPS Revision Screener Flags Strongest Movers
- 2026-10-30
COSM +34.8%, GMAB +30.3% Lead Post-EPS Revision Surges
- 2026-10-29
EAF Soars 73% on Pricing Inflection: Inside Today's Top EPS Revisions
- 2026-10-28
EAF Soars 75% on Pricing Inflection; GMAB, KIDS, SLNH Lead EPS-Revision Rally
- 2026-10-27
EAF Jumps 70.2%, HPP 23.2%, SLNH 22.6% as EPS Revisions Pay Off
- 2026-10-26
EAF Leads 5 Stock Surge on EPS Revisions: EAF +53%, HPP +26%
Recent News
- GMAB Stock Hits All-Time High After Genmabs Cancer Drug Trial Meets Primary Goals Heres What Investors Need To KnowStocktwits
- Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%Barrons.com
- Genmab stock surges 16% on positive cancer trial resultsInvesting.com
- Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck CancerBusiness Wire
- Genmab stock surges 9% following positive phase 3 ovarian cancer trial resultsInvesting.com
- Genmab Announces Rinatabart Sesutecan (Rina-S) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian CancerBusiness Wire
- European shares rise as retreating bond yields and oil prices boost risk appetiteReuters
- Genmabs Lymphoma Bet Delivers a 51% KnockoutMoby
- Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trialBioPharma Dive
- European shares gain as Genmab jumps, bond yields retreatReuters
Screen Performance
Aggregate stats across all 2130 tickers our top-EPS-revision screen has flagged over the past 219 days.
- Median return since detection
- -3.9%
- % of tickers in the green
- 41%
- Median return on winners
- +23.3%
- Large revisions captured
- 2083
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Genmab ADR's next-year EPS growth estimate?▾
As of 2026-11-06, Genmab ADR (GMAB) has a next-year EPS growth estimate of 48.58%, based on analyst consensus.
When was the latest EPS estimate revision for GMAB?▾
The most recent revision occurred on 2026-11-02, when analysts adjusted the next-year EPS growth estimate from 48.76% to 48.58%.
What sector and industry does Genmab ADR belong to?▾
Genmab ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. GMAB appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Genmab ADR (GMAB) appears here because it was detected by our daily top-EPS-revision-performer screen.